Solidarilty Wealth LLC trimmed its position in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 4.7% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,547 shares of the company’s stock after selling 127 shares during the quarter. Solidarilty Wealth LLC’s holdings in Johnson & Johnson were worth $445,000 as of its most recent filing with the Securities and Exchange Commission.
Several other large investors have also recently added to or reduced their stakes in JNJ. Palisade Capital Management LLC NJ grew its stake in shares of Johnson & Johnson by 0.3% during the first quarter. Palisade Capital Management LLC NJ now owns 93,141 shares of the company’s stock valued at $16,507,000 after purchasing an additional 250 shares during the last quarter. Lmcg Investments LLC bought a new position in Johnson & Johnson in the first quarter valued at approximately $12,462,000. Capital Wealth Planning LLC boosted its stake in Johnson & Johnson by 14.0% in the first quarter. Capital Wealth Planning LLC now owns 916,575 shares of the company’s stock valued at $162,445,000 after acquiring an additional 112,890 shares during the last quarter. Tandem Investment Advisors Inc. boosted its stake in Johnson & Johnson by 4.8% in the first quarter. Tandem Investment Advisors Inc. now owns 326,505 shares of the company’s stock valued at $57,867,000 after acquiring an additional 15,003 shares during the last quarter. Finally, Tcwp LLC bought a new position in Johnson & Johnson in the first quarter valued at approximately $946,000. 68.59% of the stock is owned by institutional investors.
Insider Activity at Johnson & Johnson
In related news, EVP Kathryn E. Wengel sold 16,410 shares of the firm’s stock in a transaction on Wednesday, November 9th. The shares were sold at an average price of $173.42, for a total value of $2,845,822.20. Following the completion of the transaction, the executive vice president now owns 71,311 shares of the company’s stock, valued at $12,366,753.62. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other news, VP Peter Fasolo sold 22,864 shares of Johnson & Johnson stock in a transaction dated Wednesday, October 19th. The shares were sold at an average price of $164.50, for a total value of $3,761,128.00. Following the completion of the transaction, the vice president now owns 114,676 shares of the company’s stock, valued at approximately $18,864,202. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Kathryn E. Wengel sold 16,410 shares of Johnson & Johnson stock in a transaction dated Wednesday, November 9th. The shares were sold at an average price of $173.42, for a total transaction of $2,845,822.20. Following the completion of the transaction, the executive vice president now directly owns 71,311 shares of the company’s stock, valued at approximately $12,366,753.62. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 118,795 shares of company stock valued at $20,230,174. Corporate insiders own 0.35% of the company’s stock.
Wall Street Analyst Weigh In
Johnson & Johnson Trading Up 0.8 %
Shares of NYSE:JNJ opened at $174.86 on Friday. Johnson & Johnson has a 12 month low of $155.72 and a 12 month high of $186.69. The company has a quick ratio of 1.18, a current ratio of 1.43 and a debt-to-equity ratio of 0.37. The company’s fifty day simple moving average is $167.63 and its 200 day simple moving average is $171.41. The firm has a market cap of $457.17 billion, a price-to-earnings ratio of 24.35, a PEG ratio of 3.42 and a beta of 0.57.
Johnson & Johnson (NYSE:JNJ – Get Rating) last issued its quarterly earnings data on Tuesday, October 18th. The company reported $2.55 EPS for the quarter, topping analysts’ consensus estimates of $2.49 by $0.06. The business had revenue of $23.79 billion for the quarter, compared to analyst estimates of $23.44 billion. Johnson & Johnson had a net margin of 19.95% and a return on equity of 35.37%. The firm’s quarterly revenue was up 1.9% on a year-over-year basis. During the same period last year, the business posted $2.60 earnings per share. As a group, research analysts forecast that Johnson & Johnson will post 10.04 EPS for the current fiscal year.
Johnson & Johnson declared that its Board of Directors has approved a share repurchase plan on Wednesday, September 14th that permits the company to repurchase $5.00 billion in shares. This repurchase authorization permits the company to buy up to 1.2% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company’s board of directors believes its stock is undervalued.
Johnson & Johnson Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 6th. Investors of record on Tuesday, November 22nd will be given a $1.13 dividend. This represents a $4.52 dividend on an annualized basis and a yield of 2.58%. The ex-dividend date is Monday, November 21st. Johnson & Johnson’s dividend payout ratio (DPR) is currently 62.95%.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- Does ASML’s November Rally Have Staying Power?
- Verra Mobility Stock Has Returned Back to the Station
- Is Advance Auto Parts a Buy After its Earnings Crash?
- BJ’s Wholesale Club: Beware The Sell-Side
- The Next Catalyst For Mullen Automotive Stock Is December 23rd
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.